Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.
Sebi bars Vijay Mallya from accessing securities market for 3 years
According to the order, Mallya is prohibited from buying, selling, or dealing in securities directly or indirectly, and from being associated with the securities market